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ABSTRACT
Background: The comparison of same,equal and low dose of misoprostol by the oral and vaginal routes for induction of 
labour at term requires further elucidation. 
Objective: To compare the efficacy and safety of 25 micrograms (ug) of oral misoprostol with 25ug vaginal misoprostol for 
induction of labor at term.
Methods: A randomised control trial that involved 169 consented women with indication for induction of labor. A total of 85 
women had oral misoprostol while 84 women had vaginal misoprostol. The oral misoprostol dose (25ug) was repeated every 
2 hours, while the vaginal dose (25ug) was repeated every 6 hours for a maximum duration of 24 hours or when need arose 
for intervention. Data was analysed using SPSS version 20. 
Results: The mean induction-delivery interval was significantly shorter (18.48 +/- 2.01 vs. 22.82 +/- 2.50, P = 0.00), with 
more vaginal deliveries (88.2% vs. 85.7%, P = 0.00) in the oral group compared to the vaginal group respectively. The 
cardiotocographic abnormalities in the vaginal group were significantly higher than the oral group (8.3% vs. 1.2%, P = 0.03). 
There were more foetal distress and meconium stained liquor in the vaginal group but not statistically significant.
Key words: Efficacy; oral misoprostol; safety; vaginal misoprostol.
Background
Induction of labor is the artificial initiation of labor at a 
viable gestational age with the aim of achieving a vaginal 
delivery in a pregnant woman with intact membranes.[1] 
In developed countries, induction of labor involves up to 
25% of all deliveries at term, while African countries tend 
to have lower rates between the range of 1.4% and 6.8%.[2‑4] 
The rate of induction of labor differs from one institution in 
Nigeria to another with an overall rate of 6.3%.[2,3] Induction 
of labor helps in reducing perinatal mortality, maternal 
complications, and improving maternal outcome.[5] However, 
it can be associated with risks, such as excessive uterine 
activity, abnormal fetal heart rate (FHR) patterns, and 
uterine rupture.[6,7] For successful induction, certain factors, 
such as parity, gestational age, and cervical status should 
be considered.[8] Indications for induction of labor can be 
maternal such as pregnancy‑induced hypertension or fetal 
such as intrauterine growth restriction.[3]
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Prostaglandins remain the single most effective means of 
achieving cervical ripening and induction labor, but they 
should be avoided in cases of scarred uteri and used with 
caution in grand multipara.[3] Misoprostol unlike dinoprostone 
is stable at room temperature, cheaper, effective, easy 
to administer, and can be given through several routes 
(oral, vaginal, sublingual, rectal, and buccal).[9,10]
In 2011, World Health Organization issued guidelines on 
induction of labor, which includes the use of oral and vaginal 
misoprostol for induction of labor and is applicable to all 
clinical settings.[3,9] Similarly, the Federal Ministry Of Health 
in Nigeria had approved the use of misoprostol for induction 
of labor and issued guidelines regarding its use.[11]
Oral misoprostol is more effective than intracervical 
prostaglandins and the current gold standard vaginal 
dinoprostone in achieving vaginal delivery within 
24 h with fewer cesarean sections.[3,9] For women with 
ruptured membranes, it exhibits similar efficacy to 
oxytocin.[9] The comparison between oral misoprostol 
and vaginal prostaglandins favored oral misoprostol with 
reduced risk of caesarean births and without increase in 
the risks of adverse maternal or perinatal outcome.[3,9,12] 
However, dreadful side effects can occur with high dose oral 
misoprostol, but with low dose the rates were equivalent 
to both placebo and the current gold standard: vaginal 
dinoprostone and may be lower compared with vaginal 
misoprostol.[3] Also, the few local studies done on induction 
of labor at term were with only vaginal misoprostol, while 
the majority of international studies done compared the two 
routes but with high doses of misoprostol (≥50 µg), with 
associated dreadful side effects of uterine hyperstimulation 
and tachysystole.[5,7,9‑15]
In view of the above evidences that lower dose misoprostol 
is associated with less dreadful side‑effects and the paucity 
of studies that compared equal and low dose misoprostol via 
the oral and vaginal route, this study aims to compare the 
safety and efficacy of 25 µg tablet misoprostol (Vanprazole by 
Cipla‑Evans pharmaceuticals India) administered in equivalent 
doses via the oral and the vaginal routes.
Methodology
Setting
The study was conducted in the delivery suite of the 
Obstetrics and Gynaecology department of Ahmadu Bello 
University Teaching Hospital Zaria (ABUTH), North Western 
Nigeria from May 2014 to June 2015. This hospital provides 
antenatal, intrapartum, postnatal, neonatal, pediatric inpatient 
and outpatient care with emergency obstetric and neonatal 
care. Some local cultural practices like early marriage, early 
pregnancies with high fertility rate are associated with medical 
conditions like hypertension in pregnancy, which frequently 
demand interventions like induction of labor.
Study population
The study population were pregnant women of parity less 
than 5 (para 0 to para 4) admitted into the labor ward with 
indication for induction of labor at term (38–42 weeks) and 
who gave a written informed consent.
Study design
The study was a randomized controlled trial. It involved 
eligible, consented patients who were randomly assigned 
into oral or vaginal misoprostol group. The allocation was 
done by sequentially opening numbered and folded forms 
with already stamped routes of administration based on a 
computer‑generated randomization table. The forms were 
sealed in opaque envelopes and picked at random from a 
basket by each patient.
Inclusion criteria
Women with term singleton fetuses, vertex presentation, a 
specific indication for induction of labor, parity of zero to four, 
bishop score of zero to five, and cardiotocographic evidence 
of a reactive fetal cardiac activity.
Exclusion criteria
Women with multiple gestation, malpresentation, nonreactive 
fetal cardiac activity, previous uterine surgeries, those already 
in labor, women with medical conditions, such as sickle 
cell anemia, mitral valve stenosis, glaucoma, and known 
hypersensitivity to prostaglandins.
Materials and Procedure
A written informed consent was obtained from every 
participant. Demographic data of the women including age, 
parity, reason for induction, gestational age, and admitting 
Bishop Score were recorded. Routine clinical evaluation and 
laboratory investigations including urinalysis, hematocrit, 
and at least one pint of compatible blood were obtained. 
A preliminary carditocographic (CTG) was done to assess 
the fetal condition, while a repeat CTG was done whenever 
abnormality in the FHR was detected and more frequently 
in the high‑risk patients.
The 25 µg misoprostol (by Pantoprazole Cipla‑Evans 
pharmaceuticals, India) was given to each participant in the oral 
group to be swallowed every 2 h with 20 ml of Nestle water, 
under direct observation for a maximum of 24 h (12 doses). 
The vaginal study group received similar dose of misoprostol 
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(25 µg) placed in the posterior vaginal fornix every 6 h for 
a maximum of 24 h (four doses). However, the next dose of 
misoprostol was withheld and the process terminated if the 
parturient transits into active phase of labor or when untoward 
observation was made requiring intervention, such as fetal 
distress, vaginal bleeding, or uterine hyperstimulation (a 
contraction lasting at least 2–3 min or more than five 
contractions per 10 min lasting greater than 45 s).
The interval from the last dose of misoprostol was at least 
6 h before labor augmentation with oxytocin was considered, 
whenever it was adjudged necessary.[16] Induction of labor 
was declared failed when active labor was not established 
after 24 h or the process abandoned (prior to onset of active 
labor) due to maternal or fetal complication. The woman was 
then given option for induction of labor after resting and 
further evaluations or an alternative mode of delivery based 
on the prevailing obstetric and clinical conditions. For women 
who proceeded into active phase of labor, partographs were 
opened and duly completed as their labor progressed.
Each parturient was monitored for uterine hyperstimulation, 
nausea, vomiting, diarrhea, fever, need for analgesia, genital 
tract lacerations, primary postpartum hemorrhages, need 
for intensive care admission, and fetal complications like 
cardiotocographic changes, meconium stained liquor, fetal 
distress, fetal demise, still birth, birth asphyxia, and need for 
admission into the special care baby unit (SCBU).
The efficacy outcomes of the induction were recorded 
as induction – delivery interval unchanged cervix after 
24 h, need for oxytocin augmentation, vaginal delivery not 
achieved within 24 h, operative vaginal deliveries, caesarean 
section rates, cumulative doses of misoprostol needed, and 
duration of latent phase of labor and retained placentae.
Besides standard management of patient in labor, uterine 
contractions, pulse, and FHR were recorded hourly in latent 
phase and 1/4 hourly in the active phase of labor. CTG was 
repeated whenever abnormal FHR (<120 or >160 bpm) 
was observed with the sonicaid and more frequently in the 
high‑risk pregnancies (such as bad outcome in previous 
pregnancy and gestational diabetes) and in those with 
evidence of fetal distress. The partograph was opened for 
each parturient as soon as they commenced active phase 
of labor and ensuing first, second, third, and fourth stages 
of labor were managed according to the departmental and 
national labor management protocols.
Sample size
The minimum sample size was determined by using the 
proportion outcome formula for a two‑sided test of 5%:
m =
(1 ) + (1 )
  










m = Size per group
c = 7.9 for 80% power
The proportion estimates were taken as:
1 = 0.82 and 2 = 0.62, when the proportion of women 
that achieved a vaginal delivery on induction with vaginal 
misoprostol from previous Zaria study was taken as 
82% (28/34) at a power of 80% to obtain a proportion 
difference of 20% (i.e., 62%) between the two groups given a 
statistical significance of 0.05.[14]
Thus, m (size per group) = 7.9 X 
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Size per the two groups = 76 × 2 = 152
The minimum of 167 subjects was needed, when an attrition 
rate of 10% was added to the calculated sample size. Thus, 
a total of 170 subjects were randomized.
Data analysis
Data was analyzed using Statistical Packages for Social 
Science (SPSS) version 20 software. The mean induction 
delivery interval and other efficacy outcomes were compared 
using the student t‑test. Complications of misoprostol due 
to different routes of administration were analyzed by their 
percentages and compared by Fisher’s test of proportions. 
A P value of < 0.05 was considered statistically significant.
Ethical consideration
Approval for this study was obtained from the Ethical 
Committee of Ahmadu Bello University Teaching Hospital 
Shika, Zaria.
Funding
All the expenses incurred in carrying out this study were 
borne by the researcher.
Results
A total of 1,383 deliveries were conducted during the study 
period. Among the 192 women slated for induction of 
labor, 170 were eligible at the point of entry into the study. 
However, one woman defaulted after allocation into the 
vaginal group, leaving 169 to receive treatment (an attrition 
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rate of less than 1%). A total of 85 pregnant women had 
25 µg oral misoprostol and 84 had 25 µg vaginal misoprostol. 
The induction rate using misoprostol was 12.22% [Figure 1].
The gestational age, bishop score, and parity of the pregnant 
women were within the same mean and standard deviation of 
the mean for both groups. These parameters were restricted 
by the study design (gestational age: 38–42 weeks, Bishop 
score: 0–5, and parity: 0–4). The mean Bishop score was not 
significantly different for both groups: 2.93 and 2.90 in the 
oral and vaginal groups, respectively [Table 1].
The commonest indication for induction of labor was 
prolonged pregnancy (83.5% and 78.5%) in both the oral 
and vaginal groups, respectively. The second commonest 
indication for induction of labor for both routes was 
pregnancy‑induced hypertension (15.3% vs. 17.9%).
The mean duration of labor was not significantly different 
for both routes (9.80 ± 1.06 vs. 10.45 ± 1.14, P = 0.18) 
for the oral and vaginal routes, respectively. The mean 
induction ‑ delivery interval was significantly shorter in the 
oral group compared to the vaginal group (18.48 ± 2.01 vs. 
22.82 ± 2.50, P < 0.001). The need for oxytocin augmentation 
was nearly the same for both groups. More doses of 
misoprostol were required to achieve delivery in the oral 
group than the vaginal (4.66 ± 0.51 vs. 2.62 ± 0.29, P = 0.00), 
respectively [Table 2].
The number of women who delivered by spontaneous 
vaginal delivery was significantly higher in the oral group 
compared to the vaginal group (relative risk, RR = 1.20; 
95% confidence interval, CI: 0.97–1.49, P = 0.00). On the 
contrary, the cesarean section rate was significantly higher 
in the vaginal group when compared to the oral route. The 
main indication for caesarean section was fetal distress, but 
was not statistically significant between the two groups. The 
percentage of failed induction of labor was not significantly 
different in both groups [Table 3].
There was a significant difference in the cardiotocographic 
(CTG) changes (three variable decelerations, two early 
decelerations, one late deceleration, and one sinusoidal 
tracing in the vaginal group against one variable deceleration 
in the oral group (RR = 0.14; 95% CI: 0.02–1.12 P = 0.03). 
More meconium stained liquor, fetal distress, and SCBU 
admissions where in the vaginal group.
The major indication for the neonatal admissions was birth 
asphyxia (more from the vaginal group), whereas the other 
two SCBU admissions were due to neonatal jaundice (from 
oral group) and risk of neonatal sepsis (from vaginal group).
There was no uterine hyperstimulation, intensive care 
unit admission, maternal death or still birth in both 
groups. One woman had primary postpartum hemorrhage 
from a cervical tear in the vaginal group. Maternal 
gastrointestinal complications were not significantly 
different between the two groups. One woman in the oral 
group had diarrhea as the side effect, whereas another 
woman in the vaginal group had nausea. The need for 
analgesia was also not significantly different for both 
routes [Table 4].
Table 2: Comparison of the efficacy of both the oral and 






Duration of labor 9.80±1.06 10.45±1.14 0.18
Induction delivery interval 18.48±2.01 22.82±2.50 0.00
Oxytocin augmentation 1.53±0.18 1.58±0.17 0.77
No. of doses of misoprostol 4.66±0.51 2.62±0.29 0.00
Table 3: Outcome of induction of labor following misoprostol 







RR (95% CI) P
Spontaneous vaginal deliveries 75 (88.2) 72 (85.7) 1.20 (0.97-1.49) 0.00
Cesarean section 10 (11.8) 12 (14.3) 1.04 (0.18-1.22) 0.00
Failed induction of labor 9 (10.6) 10 (11.9) 1.10 (0.47-2.57) 0.22
Table 4: Fetal and maternal complications following misoprostol 
administration by oral and vaginal routes




RR (95% CI) P
Meconium stained liquor 1 (1.2) 2 (2.4) 0.49 (0.05-5.35)  0.55
*CTG changes 1 (1.2) 7 (8.3) 0.14 (0.02-1.12)  0.03
Fetal distress
Apgar score
























*CTG=Cardiotocographic changes: 3 variable decelerations, 2 early decelerations, 1 late 
deceleration, and 1 sinusoidal tracing in the vaginal group, whereas in the oral group 
only one variable deceleration. SCBU=Special care baby unit
Table 1: The characteristics of the pregnant women who had 
induction of labor with 25 µg misoprostol by the oral and 
vaginal routes





Age 28.86±3.15 28.37±3.11 (25.47-28.76) 0.43
Height 1.64±0.18 1.63±0.18 (1.61-1.66) 0.62
Weight 77.61±8.47 76.76±8.43 (71.65-85.47) 0.74
Parity 2.19±0.24 1.86±0.21 (0.88-2.18) 0.10
Gestational age 39.19±4.28 38.71±4.25 (38.24-41.17) 0.66 
Bishop score 2.93±0.32 2.90±0.32 (2.47-3.35) 0.86
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Discussion
Literature has shown that the route of administration of 
misoprostol has a strong impact on the pharmacokinetic 
profile that results in different clinical efficacy with 
bioavailability of the oral misoprostol declining after 2 h and 
that of vaginal misoprostol detectable after 6 h.[16] Therefore, 
this study used the protocol for oral dosing of misoprostol 
every 2 h and vaginal dosing every 6 h.[3,16] Kundodyiwa et al. 
in a systematic review that used the same low and equal 
dose misoprostol (20 µg) via the oral and vaginal route 
reported significant differences in terms of less uterine 
hyperstimulation with FHR changes in the oral group but 
with no significant differences in other outcomes.[17]
Prolonged pregnancy was the most common indication for 
induction of labor as similarly reported by Bako et al. and 
Ekele et al.[13,18] However, an earlier Zaria study by Abdul 
et al. reported hypertension in pregnancy as the commonest 
indication unlike the present study where hypertension 
in pregnancy was the second commonest indication. This 
disparity could be explained by the fact that only term 
pregnancies were used in this study, whereas the modal 
gestational age of the women with pregnancy‑induced 
hypertension in the previous study was 36 week gestation.[14]
A shorter induction delivery‑ interval for the oral route was 
similarly reported by Kombhampati et al.[19] However, Rasheed 
et al. and Shetty et al. reported shorter induction delivery 
interval for the vaginal route against the oral route.[20,21] These 
variations in the induction delivery interval can be explained 
by the lack of homogenicity in the dosing frequency for the 
oral route. For example, the same doses of 50 µg were used 
for both the oral and the vaginal routes by Rasheed et al. but 
their dosing frequency was every 4–6 h, which was too long 
for the bioavailability of the oral drug of just 2 h.[20]
Other parameters like Bishop scores, gestational ages, and 
parity can affect the induction delivery interval if not carefully 
selected as in this study.[8] However in this study, these 
parameters were restricted by the study design (gestational 
age: 38–42 weeks, Bishop score: 0–5, and parity: 0–4). Similar 
to the report by Khadija et al. the mean gestational age, 
Bishop score and parity for both routes in this study were 
comparable with no significant difference.[22]
The more number of doses of oral misoprostol administered 
in this study was similar to the findings of Rasheed et al., 
Khadija et al., and Shetty et al.[22,20] However, differ from that 
of Hall et al. who reported consistency in the number of doses 
for both routes of administration, which can be explained by 
the use of a higher oral dose (100 µg) compared to a lower 
vaginal dose (25 µg).[23] The study by Khadija et al. showed 
similar needs for oxytocin augmentation for both routes of 
misoprostol administration.[22] However, Shetty et al. and 
Rasheed et al. showed more oxytocin requirement for the 
oral route than the vaginal route.[20,21] Both Rasheed et al. 
and Shetty et al. used a dosing frequency (4 hourly) which 
could not keep up to the recommended levels in the plasma 
to maintain contractions and hence the need for additional 
oxytocin augmentations in order to achieve deliveries. The 
oral route of misoprostol exhibits less bioavailability and 
requires more frequent dosing (2 hourly) to maintain the 
plasma peak volume required to sustain the adequate number 
of contractions needed.[16]
The higher success rate in achieving vaginal deliveries in the 
oral route compared to the vaginal was similarly reported 
by Kombhampati et al., Ratna et al., and Sultana et al.[24,25] 
However, caesarean section rate was significantly lower in 
the oral group compared to the vaginal group which was 
similar to the report by Kombhampti et al., Ratna et al., and 
Sultana et al.[19,24,25]
More cesarean sections were done in the vaginal group on 
account of fetal distress as similarly reported by Kombhampati 
et al.[19] This can be explained by the greater bioavailability of 
the vaginal dose of misoprostol.[16]
Regarding fetal safety outcomes, Kombhampati et al. similarly 
reported more clear liquor in the oral group compared to 
the vaginal group as in this study, where more meconium 
stained liquor was seen in the vaginal group.[19] The meconium 
stained liquor could be explained by the longer bioavailability 
of the vaginal route of administration of misoprostol which 
had been associated with uterine hyperstimulation, fetal 
distress, and meconium stained liquor.[16,19] Contrary, the 
Cochrane review showed more meconium stained liquor 
in the oral group.[26] However, meconium staining has been 
associated with prolonged pregnancy rather than the mode 
of the induction.[19]
The significant higher rate of cardiotocographic changes in 
the vaginal group compared to the oral group was similarly 
reported by Khadija et al.[22] Similarly, most studies reported 
increased rate of fetal distress in the vaginal group and 
uterine hyperstimulation.[3,21,26] The overall fetal safety 
outcomes were better with the oral route. Similarly, more 
safer fetal outcomes with the oral route were reported by 
Kombhampati et al., Ratna et al., and Khadija et al.[22,19,24] When 
the safety outcome of induction of labor with misoprostol is 
been contemplated upon, then the oral route has proved by 
this research and many others to be the safer option.
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Maternal gastrointestinal side‑effects of misoprostol were not 
common in this study as reported by most studies, where 
diarrhea is the commonest side effect of the oral route.[2,3,25,26] 
This could probably be due to the low dose used (25 µg) in 
this research.
Conclusion
The oral route of administration of misoprostol (25 µg) for the 
induction of labor at term is more effective than the vaginal 
route, by virtue of the higher rates of vaginal deliveries, 
lower rate of cesarean section, and shorter induction delivery 
interval. The oral route is also safer than the vaginal route 
for fetuses.
Declaration of patient consent
The authors certify that they have obtained all appropriate 
patient consent forms. In the form the patient(s) has/have 
given his/her/their consent for his/her/their images and other 
clinical information to be reported in the journal. The patients 
understand that their names and initials will not be published 
and due efforts will be made to conceal their identity, but 
anonymity cannot be guaranteed.
Limitations of the study
1. The neonates were not followed‑up over a long‑term 
period, in order to detect the rare and remote side effects 
that maybe related to the misoprostol
2. The method of analgesia used in the process of the 
induction of labor was intramuscular pentazocine unlike 
most international studies that used epidural analgesia 
for pain alleviation during labor induction.
Recommendations
1. The 25 µg misoprostol should be added to the essential 
drug list in our settings, to discourage the breaking of 
200 µg misoprostol, or dissolving it in water before use
2. The administration of the 25 µg oral dose of 
misoprostol, for induction of labor, can be a better 
choice in centers where continuous fetal monitoring 
cannot be ensured
3. The dosing regimen (25 µg every 2 h) for the oral route 
should be adhered to, rather than a higher oral dose 
with a longer dosing interval: for example 50 µg every 
4 h to comply with bioavailability of the oral route.
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